Treatment Prevents Heart Failure in Mice Following Myocardial Infarction

Treatment Prevents Heart Failure in Mice Following Myocardial Infarction

Researchers at the Baylor College of Medicine have developed a treatment that has proven to be effective in mice at preventing heart failure following a heart attack.

When patients suffer a significant heart attack, heart failure is common in humans and is often fatal. After a heart attack, patients often become progressively weaker and their health deteriorates over the space of a few years. Scars form on the heart with resultant tissue loss, inflammation, and fibrosis, which cause a progressive loss of heart function. While treatments have been developed to improve heart health, there are no treatments available to prevent heart failure.

The treatment involves the stimulation of a steroid receptor coactivator (SRC-3) using a molecule called MCB-613. MCB-613 is part of a family of molecules that are simulators for SRCs, which are involved in cellular plasticity and cell growth pathways, both in normal and abnormal tissue growth. Through the stimulation of SRC-3, the researchers were able initiate tissue repair processes and modulate the inflammatory response. The study identified no signs of toxicity from MCB-613.

The treatment is provided following a heart attack and was shown to prevent scar formation and maladaptive repair of heart tissue, which commonly leads to heart failure. This new approach therefore has the potential to save many lives. Heart failure is the leading cause of death in adults.

“In the mouse model, our team has been able to show that MCB-613 decreases damaging remodeling when given within hours after a myocardial infarction, thereby inhibiting the subsequent development of heart failure,” said Dr. Bert O’Malley, professor of molecular and cellular biology at Baylor and first author of the study. “Our findings show us that this molecule acts directly on heart tissue repair and regeneration after a severe heart attack; however, more studies are needed to fully understand the safety and efficacy before we are able to use this as a therapy in humans.”

You can read more about the study in the paper – A steroid receptor coactivator stimulator (MCB-613) attenuates adverse remodeling after myocardial infarction – which was recently published in the journal Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.2011614117

Leave a Reply